Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Glutamate (Ionotropic) Receptors
NMDA, AMPA and Kainate receptors are members of the ionotropic class of glutamate receptors. This heterogeneous group of ion channels exist as cation-selective tetramers formed by homo- and hetero-oligomeric assembly of subunits. Common structural features include an extracellular N'-terminal, three transmembrane domains, a channel lining re-entrant 'p-loop' and an intracellular C'-terminal.
Glutamate (Ionotropic) Receptor Target Files
Related Categories
Ionotropic glutamate receptors represent the major excitatory neurotransmitter pathway in the brain and consequently, they are essential for normal CNS function. However, they are also implicated in numerous pathologies including Alzheimer's disease, stroke, schizophrenia, Parkinson's disease, motor neuron disease and depression.
Receptor Classification
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Calcium Imbalance and Neuroprotective Targets
Written by E. Besancon et al
'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.